Optimizing Resources in the Pharmaceutical Public Affairs Department

To ensure organizational health and competitiveness, pharmaceutical companies must continually identify optimal resource levels for their operations. This 2012 updated benchmark study was designed to collect key staffing and investment benchmarks for U.S. based pharmaceutical Public Affairs functions.

Data from this study will allow companies to assess the efficiency of their Public Affairs functions relative to their peers.

For the purposes of this benchmarking exchange, Public Affairs was divided into six work functions:

• Government Affairs (State and Federal Government Relations and Public Policy)
• Corporate Communications – External
• Corporate Communication – Internal
• Product Communications
• Corporate Social Responsibility
• Alliance Management

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Chemical; Medical Device


Companies Profiled:
Abbott; Astellas Pharma; Boehringer Ingelheim; Cardinal Health; Celgene; Genzyme; LaVoie Group; Medtronic; Nektar Therapeutics; Novartis; Sanofi-Aventis; Shire; UCB; WellStar Health System

Study Snapshot

This research was based on survey results from 15 participants from 14 pharmaceutical and biotechnology companies.

Key topics include:

• Public Affairs: Structure and Reporting Relationships
• Public Affairs: Staffing
• Public Affairs: Investment
• Public Affairs: Consolidated Staffing and Investment Efficiency Ratios
• Lessons Learned

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.